Novavax shares jump
Digest more
The only thing that can come of this will make vaccines less insurable and less available," a vaccine expert at Children’s Hospital of Philadelphia said.
Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is soaring after the company's COVID-19 vaccine was approved by the US Food and Drug Administration (FDA).
The FDA finally approved Novavax's Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do not face
JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,
Tesla's Chinese rival Xiaomi announced its electric SUV set to compete with Tesla's Model Y will be launched Thursday. TXNM Energy agreed to be purchased by Blackstone's infrastructure division for $11.5 billion in cash and debt.
Explore more
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.
Mexico halts Brazilian poultry imports after a bird flu outbreak, the U.S. FDA conditionally approves Novavax's COVID vaccine, and allows the first Alzheimer's blood test. Meanwhile, Assura is outbid by PHP in a takeover,